Intensity Therapeutics, Inc.

INTS Nasdaq SEC CIK 1567264
Follow Intensity Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.5M −32.7% vs same quarter last year
EPS, diluted −$1.09 +29.7% vs same quarter last year
Operating cash flow −$2.5M −4.7% vs same quarter last year
Operating income −$3.6M −32.6% vs same quarter last year
Net income by quarter
−$3.2M
−$3.3M
−$2.5M
−$2.7M
−$3.1M
−$2.4M
−$3M
−$3.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$20M−$15M−$10M−$5M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$11.6M
FY24−$16.3M
FY23−$10.5M
FY22−$7.6M
FY21-